MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Current opinion in investigational drugs (London, England : 2000) · 2007

Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.

Dastidar Sunanda G, Rajagopal Deepa, Ray Abhijit

СтатьяОбзорПеревод в очереди

Аннотация

Intracellular levels of cyclic nuclec tides are closely regulated by distinct families of PD Es, which are responsible for the breakdown and degradation of cyclic nucleotides within cells. Type 4 PDEs have the potency to modulate the release of inflammatory mediators through cAMP-dependent and -independent mechanisms. Selective targeting of PDE4 is currently being investigated as a novel therapeutic approach in the treatment of inflammation-associated respiratory diseases such as asthma and COPD. The development of several PDE4 inhibitors, including roflumilast and cilomilast, reflects the success of this approach. In principle, therapeutic intervention of an inflammatory response by PDE4 inhibitors may be extended to other chronic inflammatory disease states such as psoriasis, rheumatoid arthritis and inflammatory bowel diseases (e.g., Crohns disease and ulcerative colitis). This retiiew explores the feasibility of PDE4 inhibitors as a promising alternative for therapeutic intervention in systemic inflammation and inflammation-based disease.

Для цитирования: Dastidar Sunanda G, Rajagopal Deepa, Ray Abhijit. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.. Current opinion in investigational drugs (London, England : 2000). 2007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.